NCT00923234: Combination of 5-azacitidine and Lenalidomide in Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML) Myelodysplastic Syndromes |
|
|
| Terminated | 1 | | Europe | Azacitidine, Vidaza, Lenalidomide, Revlimid | Technische Universität Dresden, Celgene Corporation | Myelodysplastic Syndromes, Acute Myelogenous Leukemia | 07/12 | 07/12 | | |
NCT00351975: Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases |
|
|
| Completed | 1 | 56 | US, Canada, RoW | Belinostat, Beleodaq, PXD 101, PXD101, Azacitidine, 5-AC, 5-AZC, U-18496, Laboratory Biomarker Analysis | National Cancer Institute (NCI) | Accelerated Phase of Disease, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blastic Phase, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndrome, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Disease, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome | 03/13 | 03/13 | | |
